Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) Debt to Equity (2018 - 2025)

Arcturus Therapeutics Holdings' Debt to Equity history spans 7 years, with the latest figure at $0.06 for Q1 2025.

  • For Q1 2025, Debt to Equity changed N/A year-over-year to $0.06; the TTM value through Mar 2025 reached $0.06, changed N/A, while the annual FY2022 figure was $0.22, 18.86% down from the prior year.
  • Debt to Equity reached $0.06 in Q1 2025 per ARCT's latest filing, down from $0.07 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.41 in Q3 2022 to a low of $0.06 in Q1 2025.
  • Average Debt to Equity over 4 years is $0.24, with a median of $0.23 recorded in 2022.
  • Peak YoY movement for Debt to Equity: skyrocketed 626.46% in 2021, then plummeted 82.59% in 2023.
  • A 4-year view of Debt to Equity shows it stood at $0.28 in 2021, then fell by 18.86% to $0.22 in 2022, then plummeted by 68.17% to $0.07 in 2023, then dropped by 10.14% to $0.06 in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Debt to Equity are $0.06 (Q1 2025), $0.07 (Q3 2023), and $0.22 (Q4 2022).